Incredible Spirits Private Limited (ISPL), a startup in the Indian alcoholic beverage industry, has launched Swigger, the country’s first-ever collection of premium Ready-to-Drink (RTD) shots.
Infused with natural and organic flavors, this meticulously crafted product makes its debut with two Gin and two Vodka variations.
The gin-based Ready-to-Drink (RTD) shots incorporate distillation techniques that infuse the flavors of Elderflower & Berries and Pink Grapefruit & Lime. On the other hand, the Vodka-based options boast variations such as Mandarin and Lime, Lychee, and Cinnamon.
Presented in 60ml double shot glasses, these flavorful SWIGGER shots come with a pull rip cap closure, ensuring a secure and hassle-free experience for consumers. This design not only maintains purity but also adds a touch of convenience to the overall enjoyment.
“We are excited to launch the country’s first spirits-based Ready-to-Drink premium shots brand. The RTD shots category is a completely new segment in India and, therefore, presents an enormous opportunity,” said Arun Raina, Co-founder, Incredible Spirits Private Limited.
Tilaknagar Industries, a leading manufacturer of Indian-Made Foreign Liquor (IMFL) and the largest producer of premium brandy in India, has made a significant investment of INR 1 crore to secure a 19.50% equity stake in Incredible Spirits Private Limited.
“Younger consumers have become more experimental which is giving a push to premium, on-the-go alco-bev products. Swigger is a first-of-its-kind offering in India’s RTD space and through this innovation, we aim to offer a safe and an enriching experience,” said Pranav Teredesai, Co-founder, Incredible Spirits Private Limited.
After this debut, there are intentions to unveil additional premium shot variations that will include Cognac, Bourbon Whiskey, Dark Rum, and Tequila.
According to the IWSR report in May 2022, India’s Ready-to-Drink (RTD) market consisted of 3 million cases in 2021. Projections suggest an annual growth rate exceeding 9% for the next five years, with an expected increase to 4.5 million cases by 2026.